Clinical trials
Completed Essential Hypertension trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
315 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 9 |
| 2005 | 9 |
| 2006 | 11 |
| 2007 | 22 |
| 2008 | 15 |
| 2009 | 17 |
| 2010 | 22 |
| 2011 | 21 |
| 2012 | 17 |
| 2013 | 14 |
| 2014 | 14 |
| 2015 | 15 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 16 |
| 2019 | 13 |
| 2020 | 5 |
| 2021 | 11 |
| 2022 | 17 |
| 2023 | 17 |
| 2024 | 14 |
| 2025 | 11 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 315 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boryung Pharmaceutical Co., Ltd | 35 |
| Novartis Pharmaceuticals | 15 |
| Takeda | 14 |
| Chong Kun Dang Pharmaceutical | 12 |
| Novartis | 12 |
| Bayer | 9 |
| Daiichi Sankyo | 9 |
| Addpharma Inc. | 6 |
| AstraZeneca | 6 |
| Sankyo Pharma Gmbh | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Essential Hypertension | 315 |
| Hypertension | 114 |
| Cardiovascular Diseases | 18 |
| Diabetes Mellitus, Type 2 | 11 |
| Vascular Diseases | 8 |
| Hyperlipidemias | 5 |
| Hypertrophy, Left Ventricular | 5 |
| Obesity | 5 |
| Diabetes Mellitus | 4 |
| Heart Failure | 4 |
Trials
Showing 76 to 100 of 315. Each trial links to its page on Pharma Observatory.
215 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.